When Altus reported to CFF that it did not have funds to continue developing the drug, CFF seized control of the asset and eventually licensed it to Alnara Pharmaceuticals, which developed the drug further and was acquired by Eli Lilly in 2010.
Upon informing CFF that they did not have resources to advance the drug development, Altus handed over the asset to CFF. Eventually, CFF licensed it to Alnara Pharmaceuticals, who continued the research and was acquired by Eli Lilly in 2010.